vs

Side-by-side financial comparison of CARVANA CO. (CVNA) and Henry Schein (HSIC). Click either name above to swap in a different company.

CARVANA CO. is the larger business by last-quarter revenue ($5.6B vs $3.4B, roughly 1.6× Henry Schein). CARVANA CO. runs the higher net margin — 15.3% vs 2.9%, a 12.4% gap on every dollar of revenue. On growth, CARVANA CO. posted the faster year-over-year revenue change (58.0% vs 7.7%). CARVANA CO. produced more free cash flow last quarter ($379.0M vs $338.0M). Over the past eight quarters, CARVANA CO.'s revenue compounded faster (35.3% CAGR vs 4.1%).

Carvana Co. is an online used car retailer based in Tempe, Arizona. Carvana was named to the 2021 Fortune 500 list, one of the youngest companies to be added to the list.

Henry Schein, Inc. is an American distributor of health care products and services, with operations in 33 countries and territories. It is the world’s largest provider of health care solutions to office-based dental and medical practitioners. For 14 consecutive years, the company has been named as one of the World's Most Ethical Companies by Ethisphere, most recently in 2025.

CVNA vs HSIC — Head-to-Head

Bigger by revenue
CVNA
CVNA
1.6× larger
CVNA
$5.6B
$3.4B
HSIC
Growing faster (revenue YoY)
CVNA
CVNA
+50.3% gap
CVNA
58.0%
7.7%
HSIC
Higher net margin
CVNA
CVNA
12.4% more per $
CVNA
15.3%
2.9%
HSIC
More free cash flow
CVNA
CVNA
$41.0M more FCF
CVNA
$379.0M
$338.0M
HSIC
Faster 2-yr revenue CAGR
CVNA
CVNA
Annualised
CVNA
35.3%
4.1%
HSIC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CVNA
CVNA
HSIC
HSIC
Revenue
$5.6B
$3.4B
Net Profit
$857.0M
$101.0M
Gross Margin
18.8%
30.9%
Operating Margin
7.6%
4.7%
Net Margin
15.3%
2.9%
Revenue YoY
58.0%
7.7%
Net Profit YoY
984.8%
7.4%
EPS (diluted)
$0.85

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CVNA
CVNA
HSIC
HSIC
Q4 25
$5.6B
$3.4B
Q3 25
$5.6B
$3.3B
Q2 25
$4.8B
$3.2B
Q1 25
$4.2B
$3.2B
Q4 24
$3.5B
$3.2B
Q3 24
$3.7B
$3.2B
Q2 24
$3.4B
$3.1B
Q1 24
$3.1B
$3.2B
Net Profit
CVNA
CVNA
HSIC
HSIC
Q4 25
$857.0M
$101.0M
Q3 25
$151.0M
$101.0M
Q2 25
$183.0M
$86.0M
Q1 25
$216.0M
$110.0M
Q4 24
$79.0M
$94.0M
Q3 24
$85.0M
$99.0M
Q2 24
$18.0M
$104.0M
Q1 24
$28.0M
$93.0M
Gross Margin
CVNA
CVNA
HSIC
HSIC
Q4 25
18.8%
30.9%
Q3 25
20.3%
30.7%
Q2 25
22.0%
31.4%
Q1 25
22.0%
31.6%
Q4 24
21.5%
31.1%
Q3 24
22.1%
31.3%
Q2 24
21.0%
32.5%
Q1 24
19.3%
31.9%
Operating Margin
CVNA
CVNA
HSIC
HSIC
Q4 25
7.6%
4.7%
Q3 25
9.8%
4.9%
Q2 25
10.6%
4.7%
Q1 25
9.3%
5.5%
Q4 24
7.3%
4.9%
Q3 24
9.2%
4.9%
Q2 24
7.6%
5.1%
Q1 24
4.4%
4.7%
Net Margin
CVNA
CVNA
HSIC
HSIC
Q4 25
15.3%
2.9%
Q3 25
2.7%
3.0%
Q2 25
3.8%
2.7%
Q1 25
5.1%
3.5%
Q4 24
2.2%
2.9%
Q3 24
2.3%
3.1%
Q2 24
0.5%
3.3%
Q1 24
0.9%
2.9%
EPS (diluted)
CVNA
CVNA
HSIC
HSIC
Q4 25
$0.85
Q3 25
$0.84
Q2 25
$0.70
Q1 25
$0.88
Q4 24
$0.75
Q3 24
$0.78
Q2 24
$0.80
Q1 24
$0.24
$0.72

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CVNA
CVNA
HSIC
HSIC
Cash + ST InvestmentsLiquidity on hand
$2.3B
$156.0M
Total DebtLower is stronger
$4.9B
$2.3B
Stockholders' EquityBook value
$3.4B
$3.2B
Total Assets
$13.2B
$11.2B
Debt / EquityLower = less leverage
1.43×
0.71×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CVNA
CVNA
HSIC
HSIC
Q4 25
$2.3B
$156.0M
Q3 25
$2.1B
$136.0M
Q2 25
$1.9B
$145.0M
Q1 25
$1.9B
$127.0M
Q4 24
$1.7B
$122.0M
Q3 24
$871.0M
$126.0M
Q2 24
$542.0M
$138.0M
Q1 24
$252.0M
$159.0M
Total Debt
CVNA
CVNA
HSIC
HSIC
Q4 25
$4.9B
$2.3B
Q3 25
$2.2B
Q2 25
$2.1B
Q1 25
$2.0B
Q4 24
$5.3B
$1.8B
Q3 24
$1.9B
Q2 24
$1.9B
Q1 24
$2.0B
Stockholders' Equity
CVNA
CVNA
HSIC
HSIC
Q4 25
$3.4B
$3.2B
Q3 25
$2.3B
$3.4B
Q2 25
$1.7B
$3.4B
Q1 25
$1.5B
$3.3B
Q4 24
$1.3B
$3.4B
Q3 24
$611.0M
$3.5B
Q2 24
$526.0M
$3.5B
Q1 24
$289.0M
$3.6B
Total Assets
CVNA
CVNA
HSIC
HSIC
Q4 25
$13.2B
$11.2B
Q3 25
$9.9B
$11.1B
Q2 25
$9.4B
$10.9B
Q1 25
$8.9B
$10.5B
Q4 24
$8.5B
$10.2B
Q3 24
$7.4B
$10.6B
Q2 24
$7.2B
$10.3B
Q1 24
$7.0B
$10.1B
Debt / Equity
CVNA
CVNA
HSIC
HSIC
Q4 25
1.43×
0.71×
Q3 25
0.64×
Q2 25
0.61×
Q1 25
0.59×
Q4 24
4.20×
0.54×
Q3 24
0.54×
Q2 24
0.54×
Q1 24
0.56×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CVNA
CVNA
HSIC
HSIC
Operating Cash FlowLast quarter
$430.0M
$381.0M
Free Cash FlowOCF − Capex
$379.0M
$338.0M
FCF MarginFCF / Revenue
6.8%
9.8%
Capex IntensityCapex / Revenue
0.9%
1.3%
Cash ConversionOCF / Net Profit
0.50×
3.77×
TTM Free Cash FlowTrailing 4 quarters
$889.0M
$573.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CVNA
CVNA
HSIC
HSIC
Q4 25
$430.0M
$381.0M
Q3 25
$345.0M
$174.0M
Q2 25
$29.0M
$120.0M
Q1 25
$232.0M
$37.0M
Q4 24
$60.0M
$204.0M
Q3 24
$403.0M
$151.0M
Q2 24
$354.0M
$296.0M
Q1 24
$101.0M
$197.0M
Free Cash Flow
CVNA
CVNA
HSIC
HSIC
Q4 25
$379.0M
$338.0M
Q3 25
$307.0M
$141.0M
Q2 25
$-2.0M
$88.0M
Q1 25
$205.0M
$6.0M
Q4 24
$36.0M
$168.0M
Q3 24
$376.0M
$117.0M
Q2 24
$332.0M
$259.0M
Q1 24
$83.0M
$156.0M
FCF Margin
CVNA
CVNA
HSIC
HSIC
Q4 25
6.8%
9.8%
Q3 25
5.4%
4.2%
Q2 25
-0.0%
2.7%
Q1 25
4.8%
0.2%
Q4 24
1.0%
5.3%
Q3 24
10.3%
3.7%
Q2 24
9.7%
8.3%
Q1 24
2.7%
4.9%
Capex Intensity
CVNA
CVNA
HSIC
HSIC
Q4 25
0.9%
1.3%
Q3 25
0.7%
1.0%
Q2 25
0.6%
1.0%
Q1 25
0.6%
1.0%
Q4 24
0.7%
1.1%
Q3 24
0.7%
1.1%
Q2 24
0.6%
1.2%
Q1 24
0.6%
1.3%
Cash Conversion
CVNA
CVNA
HSIC
HSIC
Q4 25
0.50×
3.77×
Q3 25
2.28×
1.72×
Q2 25
0.16×
1.40×
Q1 25
1.07×
0.34×
Q4 24
0.76×
2.17×
Q3 24
4.74×
1.53×
Q2 24
19.67×
2.85×
Q1 24
3.61×
2.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CVNA
CVNA

Used Vehicle Sales$4.2B74%
Wholesale Sales And Revenues$988.0M18%
Other$459.0M8%

HSIC
HSIC

Global Dental Merchandise$1.2B35%
Global Medical$1.1B31%
Global Dental Equipment$536.0M16%
Global Specialty Products$422.0M12%
Global Technology$173.0M5%
Global Value Added Services$64.0M2%
Equity Method Investee$14.0M0%

Related Comparisons